BlueRock Therapeutics is developing the CELL+GENE platform in order to create specialized allogeneic stem cell lines that do not trigger an immune response, preventing autoimmune disorders caused by foreign transplants while making it unnecessary to create induced pluripotent stem cells from the cells of every patient.
One of the key indications of Parkinson’s disease is a loss of motor function; in order to target this condition, the company has produced its own line of dopaminergic neurons, called DA01, that support motor function, replacing losses caused by stem cell exhaustion. The company has started a Phase 1 trial for these cells, which have also received FDA Fast Track designation. BlueRock is also engaged in preclinical development of stem cell lines for other nervous system disorders along with heart failure, fibrosis, and graft-versus-host disease.
BlueRock is a wholly-owned subsidiary of Bayer AG.